Compare iShares MSCI United Kingdom (FTSE) (EWU) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI United Kingdom (FTSE) vs Incyte Corporation — how do they compare? iShares MSCI United Kingdom (FTSE) trades at $48.32, while Incyte Corporation trades at $121.06 (market cap $24.54B). The key difference: iShares MSCI United Kingdom (FTSE) is trading nearer its 52-week high, Incyte Corporation nearer its low. Which is the better fit depends on your goals.
| EWU | INCY | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $48.68 | $129.93 |
52-Week Low | $40.90 | $81.61 |
Market Cap | — | $24.54B |
Enterprise Value | — | $20.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWU, the iShares MSCI United Kingdom ETF, trades at $48.37, down 0.25% on the day, with a bullish technical outlook supported by moving averages and strong trend indicators like ADX. Recent institutional activity includes Balefire LLC acquiring shares and Bank of America reducing its stake. The ETF is influenced by FTSE 100 performance, oil price volatility, and UK political developments under new Prime Minister Andy Burnham.
The outlook for EWU is cautiously optimistic, driven by bullish technical signals and exposure to UK equities, but risks from Middle East tensions, oil price swings, and political uncertainty may curb gains. Investors should weigh the ETF's diversification benefits against macroeconomic headwinds affecting British markets.
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI United Kingdom (FTSE)
EWU is a country-specific ETF that tracks the performance of the United Kingdom equity market. It provides exposure to large and mid-sized UK companies, with significant weightings in financials, energy, and healthcare, including Shell, AstraZeneca, and HSBC.
Read more on EWU →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
